BioWorld

Feb. 17, 2005

Inverness Acquiring Ischemia In Stock Deal Worth $22.4M

Cambria Plans Parkinson's, ALS Research With Three NIH Grants

Other News To Note

FibroGen Adds Institutions In $100M Round To Boost HIF Work

Selling only about 15 percent to existing investors, privately held FibroGen Inc. placed about $100 million in convertible preferred stock to advance its pipeline in a variety of programs and start more. (BioWorld Today) Read More

Pfizer Defends Celebrex As FDA Meets On Safety Of COX-2 Class

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...